The United States is buying an additional 10 million courses of Paxlovid, Pfizer’s COVID-19 treatment, the company said on Tuesday, bringing the total United States order to 20 million.
The move comes as the Biden administration seeks to increase available treatments as another tool to fight the virus.
Pfizer also said on Tuesday that delivery of the first 10 million courses had been ramped up until June, with the next 10 million arriving by September.
Experts have urged the White House to do more to ramp up production of the treatment since it can play a major role in suppressing the virus, but it is expected to be in short supply in the near term.
The White House previously said only 265,000 courses of the treatment would be available in January, amid a sharp rise in COVID-19.
Officials pointed out that a complex manufacturing process poses barriers to getting doses earlier.
“It’s still far too small and too late to meet anticipated needs,” wrote Eric Topol, professor of molecular medicine at Scripps Research, in an email after the new order was announced.
President BidenJoe BidenTrump Denounces “Low-Life Twitter” After Greene’s Account Suspends Jill Biden To Travel To Kentucky To See Tornado Damage On The Money – Biden’s Ox with Industry meat PLUS is set to comment on the omicron variant and the last of the surge response later Tuesday afternoon.
Pfizer did not quote a price for the last order of its treatment. The United States paid $ 5.295 billion for the original 10 million courses.
Trials have shown the pill to be very effective, reducing the risk of hospitalization or death by 89% in high-risk patients. It is intended to be taken within five days of the onset of symptoms.